TNF and juvenile idiopathic arthritis: For families of children and adolescents with juvenile idiopathic arthritis (JIA) or inflammatory bowel disease (IBD), our prior, qualitative research found that the decision to start TNF-α inhibitors can be particularly challenging [7, 9, 10] due to the need to balance disease severity with side-effect risks [11–13].